跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Couban Stephen H.
Project Assistant Professor
Dalhousie University
,
Pharmacology, Toxicology and Pharmaceutics
电子邮件
CS944385
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=6603944385
h-index
h10-index
h5-index
5623
引用
33
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
1084
引用
14
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
155
引用
3
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
1995 …
2021
每年的科研成果
综述
指纹
网络
科研成果
(89)
新闻 / 媒体
(3)
相似简介
(6)
指纹
深入其中 Couban Stephen H. 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Medicine and Dentistry
Acute Leukemia
23%
Acute Promyelocytic Leukemia
35%
Aggressive Lymphoma
17%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Allogeneic Stem Cell Transplantation
23%
Arsenic Trioxide
52%
Autologous Bone Marrow Transplantation
17%
Autologous Stem Cell Transplantation
33%
Autotransplantation
17%
Bendamustine
17%
Bone Marrow Necrosis
17%
Chronic Myelogenous Leukemia
17%
Cisplatin
24%
Clinical Trial
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Cytarabine
34%
Cytomegalovirus
17%
Dexamethasone
24%
Disease
29%
Disease Free Survival
20%
Engraftment
19%
Event Free Survival
24%
Filgrastim
20%
Gemcitabine
21%
Granulocyte Colony Stimulating Factor
50%
Health Care
29%
Health Care Cost
27%
Hematologic Malignancy
35%
Hematology
35%
Hematopoietic Stem Cell Transplantation
82%
Hepatic Veno-Occlusive Disease
17%
Ibrutinib
17%
Intravascular Lymphoma
17%
Leukocyte
26%
Low Molecular Weight Heparin
17%
Meta-Analysis
35%
Methotrexate
22%
Overall Survival
52%
Peripheral Blood Stem Cell
35%
Platelet
28%
Progenitor Cell
17%
Stem Cell Transplant
35%
Stiff Person Syndrome
17%
Testes
17%
Thrombocyte Transfusion
20%
Thymocyte Antibody
17%
Transplantation
81%
Tretinoin
19%
Tyrosine-Kinase Inhibitor
17%
Vein Occlusion
20%
Pharmacology, Toxicology and Pharmaceutical Science
Accessory Spleen
17%
Acute Graft Versus Host Disease
22%
Acute Leukemia
22%
Acute Lymphoblastic Leukemia
17%
Anthracycline
19%
Arsenite
35%
Bendamustine
17%
Chemotherapy
100%
Chronic Lymphatic Leukemia
17%
Cisplatin
41%
Continuous Erythropoiesis Receptor Activator
17%
Cytarabine
44%
Dexamethasone
58%
Diffuse Large B Cell Lymphoma
26%
Disease
25%
Disease Free Survival
21%
Event Free Survival
19%
Fabry Disease
17%
Fludarabine
19%
Gemcitabine
38%
Graft Versus Host Reaction
38%
Hematologic Malignancy
35%
High Dose Chemotherapy
17%
Hypertensive Factor
17%
Ibrutinib
17%
Idiopathic Thrombocytopenic Purpura
17%
Lenalidomide
35%
Lentivirus
17%
Liver Vein Obstruction
17%
Low Molecular Weight Heparin
17%
Melphalan
17%
Metastatic Breast Cancer
17%
Methotrexate
17%
Mouse
17%
Multiple Myeloma
21%
Mycophenolic Acid
17%
Overall Survival
55%
Plerixafor
17%
Prednisone
17%
Progression Free Survival
17%
Promyelocytic Leukemia
35%
Randomized Controlled Trial
20%
Remission
19%
Retinoic Acid
23%
Rituximab
22%
Romidepsin
17%
Sorafenib
17%
Tacrolimus
17%
Thymocyte Antibody
17%
Vein Occlusion
17%
Keyphrases
Acute Promyelocytic Leukemia
17%
Aggressive Lymphoma
35%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
42%
Allografting
35%
Arsenic Trioxide
17%
Bendamustine-rituximab
17%
Bleeding Symptoms
17%
Bone Marrow
25%
Bowel Involvement
17%
Canadian Consensus
17%
Catheter-related Thrombosis
35%
Clinical Trials
17%
Confidence Interval
30%
Cytomegalovirus Prophylaxis
17%
Cytomegalovirus Treatment
17%
Extramedullary Plasmacytoma
17%
Fabry Disease
17%
Filgrastim
35%
Graft-versus-host Disease (GvHD)
20%
Group Randomized
17%
Hematological Malignancies
26%
Hematopoietic Stem Cell Transplantation
47%
Hepatic Veno-occlusive Disease
17%
Ibrutinib
17%
Intravascular Large B-cell Lymphoma (IVLBCL)
17%
Lenalidomide
17%
Lentivirus
17%
Localization Studies
17%
Low Molecular Weight Heparin
17%
Marrow
17%
Marrow Transplantation
42%
Mobilized Peripheral Blood
19%
Myeloablative
18%
Newly Diagnosed
35%
Older Patients
35%
Outcome Prediction
17%
Overall Survival
26%
Pandora's Box
17%
Pathologic
17%
Patient Self-assessment
17%
Patient-level Data
17%
Plasma Mitochondrial DNA
17%
Previously Untreated
17%
Prospective Phase II Study
17%
Red Cell Exchange
17%
Salvage Chemotherapy
35%
Stiff Person Syndrome
17%
Transformed Indolent Lymphoma
17%
Treatment Outcome
23%
Venous Disease
20%
